clinical trial · NCT06586515
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Eli Lilly and Company·phase1·recruiting·n = 630
Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal CancerLY3962673CetuximabGemcitabinenab-paclitaxelOxaliplatinleucovorinIrinotecan5-fluorouracil
brief summary
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
started
Sep 12, 2024
primary completion
Mar 1, 2029
completion
Mar 1, 2029
last updated
Apr 20, 2026
official title
A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol